Identification of tumor antigen derived peptides having the potential to promise candidates for cancer vaccine therapy from prostate cancer patients研究代表者南高文(MINAMI TAKAFUMI)

鉴定出肿瘤抗原衍生肽有可能成为前列腺癌患者癌症疫苗治疗的候选者首席研究员 MINAMI TAKAFUMI

• 批准号: 22791505
• 负责人: MINAMI Takafumi
• 金额: $ 2.08万
• 依托单位: Kinki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791505/
• 关键词: 前立腺癌; 癌ワクチン; HLA-A3 supertype alleles; ペプチドワクチン; テーラーメイド

Peripheral blood mononuclear cells(PBMCs) were obtained from prostate cancer patients. The PBMCs were prepared by Ficoll-Conray density gradient centrifugation. The expression of HLA-A11,-A31, and-A33 molecules on the PBMCs was determined by flow cytometry using these antibodies-anti-HLA-A11,-A31,-A33-and FITC-conjugated anti-mouse IgG monoclonal antibodies. 3 prostate cancer-related antigens prepared based on the binding motifs to the MHC-class I alleles. It is predicted as a peptide candidate that be identified induction of specific CTL with EZHp_<733-741> peptide in CTL assay, and can apply to a cancer vaccine treatment.

外周血单核细胞（PBMC）取自前列腺癌患者。通过Ficoll-Conray密度梯度离心制备PBMC。使用这些抗体-抗-HLA-A11、-A31、-A33-和FITC-缀合的抗小鼠IgG单克隆抗体，通过流式细胞术测定PBMC上HLA-A11、-A31和-A33分子的表达。基于 MHC I 类等位基因的结合基序制备 3 种前列腺癌相关抗原。预计其作为候选肽，在CTL测定中被鉴定为用EZHp_<733-741>肽诱导特异性CTL，并且可应用于癌症疫苗治疗。